Related Experiment Videos
Anemia in chronic congestive heart failure: frequency, prognosis, and treatment
Martino Crosato1, Wolfram Steinborn, Stefan D Anker
1Imperial College, National Heart & Lung Institute, Department of Clinical Cardiology, London, UK.
Insights
Anemia affects 10-20% of chronic heart failure (CHF) patients, worsening symptoms and survival. Early studies suggest treating anemia with erythropoietin and iron may improve exercise capacity and reduce symptoms.
Area of Science:
- Cardiology
- Hematology
- Internal Medicine
Background:
- Chronic heart failure (CHF) is a significant cause of illness and death.
- Anemia is a common complication in CHF, affecting 10-20% of patients.
- The exact causes of anemia in CHF are often unclear, with 'anemia of chronic illness' being the most frequent diagnosis.
Purpose of the Study:
- To investigate the impact of anemia on CHF patients.
- To explore potential treatments for anemia in CHF.
- To evaluate the efficacy of erythropoietin and iron in improving CHF patient outcomes.
Main Methods:
- Review of existing literature on anemia in CHF.
- Analysis of pilot studies on anemia correction in CHF.
- Emphasis on the need for large-scale, randomized, placebo-controlled trials.
Main Results:
- Low hemoglobin levels in CHF correlate with reduced exercise capacity, increased symptoms, and poorer survival rates.
- Pilot studies indicate that correcting anemia with erythropoietin and iron may enhance exercise tolerance and alleviate symptoms.
- Further research is required to confirm these findings.
Conclusions:
- Anemia is a prevalent and serious complication of chronic heart failure.
- Erythropoietin and iron therapy show promise for improving CHF patient outcomes.
- Larger clinical trials are necessary to establish anemia treatment as a standard therapy for CHF.
Abstract:
Chronic heart failure (CHF) is a leading cause of morbidity and mortality. Although a precise definition for a cut-off value of hemoglobin level for anemia is still lacking, it has recently been found to be a common complication in CHF, occurring in 10-20% of patients. There are several possible pathogenetic mechanisms for anemia in CHF, and a precise underlying cause is found in only a minority of patients. In CHF, more than 50% of anemia cases are considered to be 'anemia in chronic illness'. In CHF patients, low hemoglobin values directly relate to poor peak oxygen consumption, disabling symptoms, and impaired survival. Recent pilot studies showed that correction of anemia with erythropoietin and iron may lead to improvement in symptoms and exercise capacity. These issues need to be tested in larger, double-blind, randomized, placebo-controlled trials before anemia treatment becomes routine in patients with CHF.